Patient-Preferred Therapy in ALK+ Lung Cancer

Dr. Mark Kris underscores the advantages of crizotinib and other ALK-targeted therapies for ALK+ lung cancer and looks askance at recent data on toxicity levels and cost-effectiveness of testing.
Source: Medscape Pathology and Laboratory Medicine Podcast - Category: Laboratory Medicine Authors: Source Type: podcasts